Skip to content


Epclusa (velpatasvir) is a small molecule pharmaceutical. Velpatasvir was first approved as Epclusa on 2016-06-28. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Epclusa's patents are valid until 2034-01-30 (FDA).
Trade Name Epclusa
Common Name Velpatasvir
Indication chronic hepatitis c, hepatitis c
Drug Class Antivirals: NS5A inhibitors
Get full access now